



## **Supplementary Material for:**

A proposed simple screening method to determine relative contributions of CYP3A4 and CYP3A5 to drug metabolism *in vitro*

Jun Matsumoto, Hiroyoshi Nakamura, Su Nwe San, Hikari Sato, Manami Takezawa,  
Ryuto Kishi, Yutaro Kito, Junko Sugano, Mai Izuki, Nao Yanagisawa, Naoki Ikeda,  
Yusuke Saito, Yoshinori Kato, Harumi Yamada, Masachika Fujiyoshi, Noritaka Ariyoshi



**Supplementary Fig. 1.** Optimization of the screening method using recombinant CYP3As. Determination of the appropriate incubation time (A) and recombinant CYP3A content (B). Open and closed circles represent CYP3A4 and CYP3A5, respectively. Effects of the concentration of the DMSO (C), ethanol (D), or methanol (E) solvent on CYP3A activity. The minimum DMSO concentration was 0.05 (w/v) % since L-PPXE was dissolved DMSO. Percent changes were calculated based on control values. All values are presented as the mean  $\pm$  SD. Single, double, and triple asterisks indicate  $P < 0.05$ ,  $P < 0.01$ , and  $P < 0.001$ , respectively.



**Supplementary Fig. 2.** (A), Luminescence activity-concentration plots of L-PPXE metabolism by CYP3A4 and CYP3A5. L-PPXE metabolism by CYP3A4 and CYP3A5 was determined at varying concentrations ranging from 5 to 100  $\mu\text{M}$ . Dose-inhibition curves in L-PPXE metabolism by tacrolimus (B), midazolam (C), and CYP3cide (D). Percent changes were calculated based on control values. Open and closed circles represent CYP3A4 and CYP3A5, respectively. All values are presented as the mean  $\pm$  SD.

**Supplementary Table 1.** Consistency of data in our screening method with drug information on whether drugs are metabolized by CYP3As.

<b>Drug name</b>	<b>This study</b> (Metabolized by CYP3As)	<b>DI</b> (Metabolized by CYP3As)	<b>Consistency</b>
<b>Apixaban</b>	Yes	Yes	Yes
<b>Ethosuximide</b>	No	No	Yes
<b>Lapatinib</b>	Yes	Yes	Yes
<b>Sodium valproate</b>	No	No	Yes
<b>Sorafenib</b>	Yes	Yes	Yes
<b>Sumatriptan</b>	No	No	Yes
<b>Telaprevir</b>	Yes	Yes	Yes
<b>Topiramate</b>	Yes	Yes	Yes
<b>Vaniprevir</b>	Yes	Yes	Yes

DI, Drug information provided by pharmaceutical companies.